Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its ...

Despite these promising developments, Archila remains cautious due to near-term challenges associated with Syfovre, another key product for Apellis. The growth dynamics of Syfovre are seen as a ...

Today's label printers range from small desktop units for file-folder paper labels to industrial-grade ones for labeling cables with plastic strips. Here's how to pick the right labeler ...

Earlier this year, Apellis Pharma became the first company to claim FDA approval for a drug to treat the condition, Syfovre (pegcetacoplan), which also targets the complement system. Syfovre needs ...